

To whom it may concern,

Re: TSE declaration for Moorfields Pharmaceuticals products

All Moorfields Pharmaceuticals products comply with the EMEA/410/01 “*Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human Veterinary Medicinal Products*” and with the scientific principles, which include a number of control measures such as sourcing and quality control of starting materials, and the design and control of the manufacturing procedure. Any changes to this Note for Guidance will be followed and its application verified.

In line with the requirements of the above mentioned EMEA Note for Guidance, Moorfields Pharmaceuticals assesses any TSE-relevant animal derived materials that are used for the preparation of our products to minimise the risk of transmission of TSE.

By adhering to our quality assurance system, Moorfields Pharmaceuticals concludes that the risk of transmitting TSEs via Moorfields Pharmaceutical is negligible.

Yours sincerely,

n. ghedia 18 JUL 2011

Nisha Ghedia

Moorfields Pharmaceuticals

QA Executive

34 Nile Street, London, N1 7TP, UK

Tel: + 44 20 7684 8559

Fax: + 44 20 7684 8578

E-mail: Nisha.Ghedia@moorfields.nhs.uk